ABOUT MULTIPLE ENDOCRINE NEOPLASIA

A thyroid nodule. Elevated calcium. A family pattern that keeps recurring across generations. The specific RET or MEN1 variant determines not just the diagnosis — but the clinical timeline.

Whole genome sequencing identifies MEN1 and RET variants that enable codon-specific risk stratification and direct surgical timing — turning genetic information into lifesaving clinical decisions.

MEN1
RET

About this condition

Multiple Endocrine Neoplasia (MEN1/MEN2)

Multiple Endocrine Neoplasia comprises two genetically and clinically distinct syndromes. MEN1 is caused by pathogenic variants in MEN1, encoding menin — a nuclear scaffold protein involved in transcriptional regulation, DNA repair, and chromatin remodeling. MEN1 functions as a tumor suppressor with no identifiable mutation hotspots; over 1,300 pathogenic variants are distributed across the entire coding region. MEN2 is caused by gain-of-function pathogenic variants in RET, a receptor tyrosine kinase involved in cell growth signaling. Unlike MEN1, RET variants constitutively activate kinase function, driving uncontrolled cell proliferation. MEN2 variants cluster in specific exons (10, 11, 13–16), with strong genotype-phenotype correlation.

MEN1 affects approximately 1 in 30,000 individuals and is characterized by tumors of the parathyroid (~95% of carriers by age 50), anterior pituitary (~40%), and pancreatic islets/duodenum (~40%), plus carcinoid tumors, adrenocortical tumors, and non-endocrine features including facial angiofibromas and meningiomas. MEN2 affects 1 in 30,000–50,000 individuals and includes three subtypes: MEN2A (medullary thyroid carcinoma, pheochromocytoma, parathyroid adenoma), FMTC (familial medullary thyroid carcinoma only), and MEN2B (medullary thyroid carcinoma, pheochromocytoma, mucosal neuromas, marfanoid habitus — the most aggressive form). Penetrance is >90% for both syndromes.

A MEN2/RET diagnosis directly determines surgical decision-making in a way few genetic conditions do. The specific RET codon mutation predicts the aggressiveness of medullary thyroid carcinoma and the earliest age at which prophylactic thyroidectomy should occur: M918T (MEN2B) requires surgery within the first 6 months of life; C634R and other high-risk codons by age 5; moderate-risk mutations may allow delayed surgery with calcitonin surveillance. MEN1 diagnosis triggers lifelong biochemical and imaging surveillance for parathyroid, pituitary, and pancreatic tumors. Both syndromes benefit from cascade testing identifying relatives before tumor development.

MEN1 and MEN2 are distinct syndromes: MEN2 has strong RET codon-phenotype correlation guiding surgical timing; MEN1 has no reliable genotype-phenotype correlation, requiring uniform surveillance across all carriers. This distinction is clinically critical.

Gene locus: MEN1 (11q13.1), RET (10q11.21)

MEN1 testing is challenging because pathogenic variants lack mutation hotspots. Standard MEN1-only panels may miss ~10% of clinical cases.

MEN1 and MEN2 require comprehensive gene coverage

MEN1 is particularly challenging to test because pathogenic variants are distributed throughout the entire 20-kb coding region with no identifiable hotspots. Approximately 10% of patients meeting clinical MEN1 criteria have no detectable MEN1 variant — suggesting deep intronic, regulatory, or alternative gene involvement not captured by standard sequencing. Large MEN1 deletions require separate copy number analysis. RET testing is more straightforward due to hotspot clustering, but a panel testing only RET would miss MEN1 entirely — and vice versa. Whole genome sequencing captures complete information for both genes simultaneously.

RET codon determines thyroidectomy timing; MEN1 finding triggers lifelong surveillance

For MEN2/RET carriers, the specific codon mutation directly determines the timing of prophylactic thyroidectomy — the most direct genotype-to-surgical-decision relationship in medicine. M918T (MEN2B) requires thyroidectomy by 6 months of age; high-risk codons like C634R by age 5; moderate-risk mutations by early childhood with calcitonin surveillance. For MEN1 carriers, genetic confirmation triggers lifelong surveillance for parathyroid, pituitary, and pancreatic tumors. Both syndromes benefit from cascade testing — identifying relatives at risk before the first clinical manifestation.

A thyroid nodule. Elevated calcium. A family pattern that keeps recurring across generations. The specific RET or MEN1 variant determines not just the diagnosis — but the clinical timeline.

Multiple Endocrine Neoplasia (MEN1/MEN2)

MEN1 testing is challenging because pathogenic variants lack mutation hotspots. Standard MEN1-only panels may miss ~10% of clinical cases.

MEN1 and MEN2 require comprehensive gene coverage

RET codon determines thyroidectomy timing; MEN1 finding triggers lifelong surveillance

Others in Hereditary Cancer

One test. A lifetime of answers.